Abstract
Significance That a retinal image based Deep Learning (DL) Cardiac BioAge Model may be a useful novel tool that can personalise an individual’s risk of Atherosclerotic cardiovascular disease (ASCVD) events.
Purpose To determine whether the results issued by our DL Cardiac BioAge model are consistent with the known trends of cardiovascular disease (CVD) risk and the biomarker Leucocyte Telomere Length, in a cohort of individuals from the UK Biobank.
Methods Individuals were divided by sex, ranked by Z adjusted log T/S Leucocyte Telomere length (LTL) and then grouped into deciles. The retinal images were then presented to the DL model and individual’s Cardiac BioAges determined. Individuals within each LTL decile was then ranked by Cardiac BioAge, and the mean of the CVD risk biomarkers in the top and bottom quartiles compared. The relationship between an individual’s Cardiac BioAge, the CVD biomarkers and LTL were determined using traditional correlation statistics.
Results The DL Cardiac BioAge model was able to accurately stratify individuals by the traditional CVD risk biomarkers, and for both males and females those issued with a Cardiac BioAge in the top quartile of their chronological peer group had a significantly higher mean SBP, HbA1C and 10-year Pooled Cohort Equation ASCVD scores compared to those individuals in the bottom quartile. Cardiac BioAge was associated with LTL shortening for both males and females. (Males: -0.220, P <0.001; Females: -0.174, P <0.001)
Conclusion In this small cohort study increasing CVD risk; as assessed by both traditional biomarkers, ASCVD risk scoring and a DL Cardiac BioAge CVD risk model, was inversely related to LTL. At a population level our data supports the growing body of evidence that suggests that LTL shortening is a surrogate marker for increasing CVD risk and that this risk can be captured by our novel DL Cardiac BioAge model.
Competing Interest Statement
Ehsan Vaghefi and David Squirrell are the co-founders of Toku Eyes. Songyang An is a member of the AI engineering team at Toku Eyes. Rini Corbett: Employment- Toku Eyes
Funding Statement
Toku Eyes has funded this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was enabled by the UK Biobank, which is available publically for research through it data guardian
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This study was enabled by the UK Biobank, which is available publically for research through it data guardian